Original Article
Treatment of Children and Young Adults with Early-Stage Non-Hodgkin's Lymphoma
N Engl J Med 1997; 337:1259-1266October 30, 1997
- Abstract
Background
Children and young adults with early-stage non-Hodgkin's lymphoma have an excellent prognosis, but treatment is prolonged and is associated with many side effects. We performed two studies to determine whether therapy could be simplified.
Methods
Between 1983 and 1991, we conducted two consecutive trials in children and young adults (age, <21 years) with early-stage non-Hodgkin's lymphoma. In the first trial, patients were treated for 9 weeks with induction chemotherapy consisting of vincristine, doxorubicin, cyclophosphamide, and prednisone, followed by 24 weeks of continuation chemotherapy with mercaptopurine and methotrexate. Half the patients were randomly assigned to receive involved-field irradiation. In the second trial, after the 9 weeks of induction chemotherapy, the patients were randomly assigned to receive 24 weeks of continuation chemotherapy or no further therapy.
Results
A total of 340 patients were enrolled in the two trials, 12 of whom did not have complete remissions. One hundred thirteen patients received nine weeks of chemotherapy without radiotherapy, 131 received eight months of chemotherapy without radiotherapy, and 67 received eight months of chemotherapy with radiotherapy. At five years, the projected rates of continuous complete remission were 89, 86, and 88 percent for the three groups, respectively. At five years, event-free survival among the patients with early-stage lymphoblastic lymphoma was inferior to that among the patients with other subtypes of lymphoma (63 percent vs. 88 percent, P<0.001). Continuation therapy was effective only in patients with lymphoblastic lymphoma.
Conclusions
A nine-week chemotherapy regimen without irradiation of the primary sites of involvement is adequate therapy for most children and young adults with early-stage, nonlymphoblastic non-Hodgkin's lymphoma.
Media in This Article
Figure 1
Design of Two Consecutive Trials of Therapy for Patients with Early-Stage Non-Hodgkin's Lymphoma, with the Treatment Assignments and Outcomes Shown for All 340 Eligible Patients.Figure 2
Life-Table Analysis of Continuous Complete Remission (Panel A) and Overall Survival (Panel B) after Randomization in Patients with Early-Stage Non-Hodgkin's Lymphoma, According to Treatment Group.Article Activity
- Article
The improvement over the past two decades in the outcome for children and young adults with non-Hodgkin's lymphoma is one of the success stories of pediatric oncology. Nearly three fourths of all children and young adults with this disease who undergo current therapeutic regimens are cured, including most of those who present with local or regional (early-stage) disease confined to sites associated with a favorable prognosis.1-7
Because of a desire to spare young patients with early-stage non-Hodgkin's lymphoma from the adverse acute and late effects of therapy, we conducted two consecutive studies designed to maintain the high cure rate while reducing the intensity and duration of therapy. The first trial demonstrated that an eight-month chemotherapy regimen without irradiation of the primary sites of involvement was as effective as chemotherapy plus radiotherapy.6 The second trial was designed to determine whether six months of continuation treatment with two drugs is a necessary component of the regimen. We report the results of this study, as well as the updated results of the first trial.
Methods
Patients
Children and young adults were enrolled in the first trial between April 1983 and May 1987 and were enrolled in the second trial between June 1987 and November 1991 at all institutions that are members of the Pediatric Oncology Group (see the Appendix). Previously untreated children and adults younger than 21 years of age who had biopsy-confirmed non-Hodgkin's lymphoma of any histologic type were eligible for enrollment.
Studies and procedures performed to determine the stage of disease included a history taking and physical examination, blood counts, bone marrow aspiration, lumbar puncture for examination of a cytocentrifuged specimen of cerebrospinal fluid, chest radiography, and radionuclide bone scanning. Additional studies, including computed tomography or magnetic resonance imaging, were performed in some patients, particularly those with primary tumors in the head and neck region or abdomen. The clinical stage was determined according to a staging system described previously.8 Patients meeting the criteria for early-stage disease were eligible for the trials. Specifically, eligible patients were those who had stage I disease, with lymphoma confined to a single nodal or extranodal area (whether resected or not), or stage II disease, with a single tumor and regional lymph-node involvement, two or more sites of disease confined to one side of the diaphragm, or lymphoma of the gastrointestinal tract that had undergone grossly complete (>90 percent) resection. Excluded were patients with more advanced disease (stage III or IV), including those with mediastinal or massive intraabdominal primary tumors, lymphoma on both sides of the diaphragm, or involvement of the bone marrow or central nervous system. The histologic findings were reviewed centrally, and the diagnostic specimens were classified according to the working formulation for clinical use.9
Randomization and Treatment
The design of the two trials is shown in Figure 1Figure 1
Design of Two Consecutive Trials of Therapy for Patients with Early-Stage Non-Hodgkin's Lymphoma, with the Treatment Assignments and Outcomes Shown for All 340 Eligible Patients.. In the first trial,6 patients were randomly assigned to receive either eight months of chemotherapy with radiotherapy or eight months of chemotherapy alone. Radiotherapy, which was administered during induction chemotherapy, consisted of irradiation of the involved field with a total dose of 27 Gy in 18 150-cGy fractions during a period of three and a half weeks. In the second trial, all patients received identical regimens of induction and consolidation chemotherapy for nine weeks without irradiation. Remission was assessed after the nine-week period by clinical examination and repeated staging studies. Patients with complete remissions at this time were then randomly assigned to receive an additional 24 weeks of chemotherapy with mercaptopurine and methotrexate, as administered in the first trial, or no further therapy.The chemotherapy regimens are shown in Table 1Table 1
Treatment Regimens for Patients with Early-Stage Non-Hodgkin's Lymphoma.. Induction–consolidation chemotherapy consisted of four drugs given for 9 weeks, and continuation chemotherapy consisted of daily oral mercaptopurine and weekly oral methotrexate given for 24 weeks. Central nervous system prophylaxis was administered only in patients with primary tumors in the head and neck region. The drugs, doses, and schedule of administration were identical in the two trials, except for central nervous system prophylaxis. The protocols were approved by the institutional review board at each participating center, and all patients or their parents gave informed consent.Statistical Analysis
We had demonstrated in the first trial that irradiation of primary sites can be safely omitted from the treatment of children with early-stage non-Hodgkin's lymphoma.6 The second trial was designed to investigate the contribution of 24 weeks of continuation therapy as used in the earlier trial. In addition, we planned a comparison of the efficacy of eight months of chemotherapy combined with radiotherapy (the standard treatment in the first trial) with nine weeks of chemotherapy alone (the least intensive of the treatments) to assess any loss of overall efficacy resulting from two successive reductions in treatment. This analysis was intended to protect against the possibility that two small decrements in efficacy, neither one significant alone, would result in a significant overall decrement in efficacy when combined.
Since the disease is rare, we elected to include patients from the first trial in the analysis of the second trial and used a study design in which two patients were randomly assigned to nine weeks of chemotherapy without radiotherapy for each patient assigned to eight months of chemotherapy without radiotherapy. Because the study question is negative (Is a less intensive therapy as effective?), we considered a one-sided P value of 0.10 or less in favor of eight months of chemotherapy as evidence of the efficacy of continuation therapy. We planned for a power of 90 percent to detect this difference. Allowing for the data already accrued, assuming a 95 percent rate of continuous complete remission at two years for the patients receiving continuation therapy and an 85 percent rate for those not receiving continuation therapy, and assuming an enrollment of 36 patients per year, we determined that an additional 183 patients would be required, with a final analysis planned two years after the completion of enrollment. The two-to-one randomization scheme increased the power obtained with the usual one-to-one randomization and also increased the power of the secondary comparison (eight months of chemotherapy with radiotherapy vs. nine weeks of chemotherapy without radiotherapy).
The analysis is based on follow-up data as of April 1996. All eligible patients were evaluated according to the treatment assigned at randomization. The dependent variable for efficacy was complete continuous remission — the time from a complete remission to the last contact, a relapse at any site, the development of a second cancer, or death, whichever came first. In the analysis of the outcome according to the histologic subtype of lymphoma, the dependent variable was event-free survival — the time from the initiation of therapy to treatment failure for any reason or the last contact, whichever came first. All comparisons were made with the use of the log-rank test,10 and life tables for continuous complete remission, event-free survival, and overall survival were constructed according to the method of Kaplan and Meier,11 with standard errors calculated as described by Peto et al.12 All comparisons of efficacy were conducted as one-sided tests. Comparisons of outcome according to histologic type were omnibus (all-sided) tests. One-sided confidence intervals for the outcome in the patients treated with nine weeks of chemotherapy without radiotherapy (the least intensive of the treatments) were also determined.
Results
Patients
Between April 1983 and May 1987, 150 patients were enrolled in the first trial, and between June 1987 and November 1991, 205 patients were enrolled in the second trial. Fifteen patients were found to be ineligible on review and were excluded from the analysis: in seven, the diagnosis of non-Hodgkin's lymphoma could not be confirmed, and eight did not have early-stage disease. The 340 eligible patients in the two trials included 243 males (71 percent) and 97 females (29 percent), with a median age of 10 years (range, 16 months to 20 years; mean, 10 years). One hundred thirty-eight patients had stage I non-Hodgkin's lymphoma, and 202 had stage II disease. The distribution of cases according to the primary site of tumor and histologic subtype is shown in Table 2Table 2
Distribution of Patients with Early-Stage Non-Hodgkin's Lymphoma According to the Primary Site and Histologic Subtype of Tumor..Twenty-nine patients were not randomly assigned to a treatment group. Seven patients in the first trial had primary lymphomas of bone and, according to the design of that trial,6 were excluded from randomization and treated with chemotherapy for eight months and radiotherapy (total dose, 37.5 Gy). Six other patients were not randomized: one was treated with irradiation, and five were treated without irradiation. In the second trial, 12 patients did not have complete remissions and were thus ineligible for random assignment, and 4 patients declined randomization. Data from these 29 patients are not included in any of the randomized comparisons of treatment efficacy but are included in other analyses of outcome in which the treatment assignment was not relevant.
A total of 311 patients were randomly assigned to treatment in the two studies (Figure 1). In the second trial, 113 patients were randomly assigned to receive nine weeks of chemotherapy alone, and 69 were assigned to receive eight months of chemotherapy. (The imbalance in the treatment assignments reflects the two-to-one randomization scheme.) In the analysis of the outcome, the 62 patients from the first trial who were assigned to treatment with eight months of chemotherapy without radiotherapy were included with the 69 patients assigned to this treatment in the second trial, so that a total of 131 patients were assigned to this treatment. Finally, 67 patients from the first trial were randomly assigned to receive eight months of chemotherapy and radiotherapy, and this treatment served as the standard against which the other treatments were evaluated.
Outcome
The outcome for all patients is shown in Figure 1, Figure 2AFigure 2
Life-Table Analysis of Continuous Complete Remission (Panel A) and Overall Survival (Panel B) after Randomization in Patients with Early-Stage Non-Hodgkin's Lymphoma, According to Treatment Group., Figure 2B, and Table 3Table 3
Outcome of Early-Stage Non-Hodgkin's Lymphoma, According to Treatment and Histologic Subtype of Tumor.. A total of 54 patients had adverse events. Twelve did not have complete remissions, 38 had recurrent lymphoma after a complete remission, 1 died of sepsis during a complete remission, and 3 had secondary leukemia (acute nonlymphocytic leukemia in 1 patient, biphenotypic leukemia in 1, and secondary T-cell acute lymphoblastic leukemia in 1 patient with small-noncleaved-cell lymphoma). Of the 38 patients who had relapses, 10 had recurrences at the primary site, 7 in the bone marrow, 5 in the central nervous system, 3 in the testis, and 13 in various nodal and extranodal sites.The results of a life-table analysis of the outcome according to the treatment are shown in Figure 2A and Figure 2B. At five years, the mean (±SE) projected rate of continuous complete remission was 89±4 percent for patients treated with nine weeks of chemotherapy without radiotherapy, 86±4 percent for those treated with eight months of chemotherapy without radiotherapy, and 88±4 percent for those treated with eight months of chemotherapy with radiotherapy (Figure 2A). There was no difference in the outcomes for patients receiving nine weeks of chemotherapy without radiotherapy and those receiving eight months of chemotherapy without radiotherapy (P = 0.66). Nor was there a difference in the outcomes for patients receiving nine weeks of chemotherapy without radiotherapy and those receiving our previous standard therapy — eight months of chemotherapy with radiotherapy (P = 0.48) (Table 3). A life-table analysis of overall survival according to treatment is shown in Figure 2B. The 12 patients who did not have complete remissions and the 17 who were not randomly assigned to a treatment group (all of whom have had continuous complete remissions) are not included in the life-table analyses shown in Figure 2A and Figure 2B. Although the overall results must be viewed as inconclusive, one can infer that nine weeks of chemotherapy without radiotherapy is sufficient, because we can state with 95 percent confidence that with this therapy, the projected five-year survival exceeds 94 percent and the five-year rate of continuous complete remission exceeds 83 percent.
Considering that all 142 eligible patients enrolled in the first trial had complete remissions, we were concerned that induction therapy was unsuccessful in 12 of 198 patients in the second trial. An analysis of the characteristics of the patients enrolled in the two trials failed to account for this difference, and it remains unexplained. To assess the likelihood that our conclusions would have been altered had we included in the analysis the 12 patients who did not have complete remissions, we analyzed the data with the 12 patients assigned to treatment in the two-to-one ratio prescribed by our design. Only if all 12 of these patients had been assigned to nine weeks of chemotherapy without continuation therapy (a circumstance with a probability of less than 1 percent) would the P value have been less than 0.10.
When all 340 eligible patients are considered together, the projected event-free survival at five years was 85±2 percent, and only 4 patients (of 211 at risk) had adverse events more than five years after the diagnosis (Figure 3AFigure 3
Life-Table Analysis of Event-free Survival (Panel A) and Overall Survival (Panel B) for All 340 Patients with Early-Stage Non-Hodgkin's Lymphoma, According to the Histologic Subtype.). Salvage therapy was apparently successful for more than half the patients who did not have complete remissions or had recurrent disease. The projected overall survival nine years after the diagnosis of non-Hodgkin's lymphoma was 92±3 percent (Figure 3B).Analysis of the results of treatment according to the histologic subtype of non-Hodgkin's lymphoma revealed important differences (Figure 3A and Figure 3B). Although induction therapy was successful in all 50 patients with early-stage lymphoblastic lymphoma (as compared with a success rate of 96 percent for those with other histologic subtypes), the event-free survival for these patients was inferior to that for patients with other subtypes of lymphoma. Only 63 percent of the patients with early-stage lymphoblastic lymphoma were projected to survive without a recurrence of disease for five years, as compared with a projected 89 percent of patients with small-noncleaved-cell lymphomas and 88 percent of those with large-cell lymphomas (P<0.001). It is apparent that among patients with lymphoblastic lymphoma, those who receive eight months of chemotherapy (including six months of continuation chemotherapy with or without radiotherapy) have a better outcome than those who receive nine weeks of chemotherapy without continuation chemotherapy (Table 3). In contrast, for the majority of patients with other subtypes of non-Hodgkin's lymphoma, no significant benefit was derived from six months of continuation therapy (Table 3). We can conclude (with 95 percent confidence) that the five-year rate of continuous complete remission for patients with nonlymphoblastic lymphoma who receive nine weeks of chemotherapy (4 failures among 89 patients) exceeds 92 percent. Salvage therapy for the patients with early-stage lymphoblastic lymphoma who had relapses appeared to be effective, because an analysis of overall survival revealed no differences according to the histologic subtype (P = 0.24) (Figure 3B).
Side Effects
Fifteen of 131 patients (11 percent) had severe or life-threatening granulocytopenia during continuation therapy, and 2 had severe central nervous system toxic effects (hemiparesis in 1 patient and encephalopathy in the other). Two patients reported severe nausea and vomiting during continuation therapy; severe anemia, stomatitis, ileus, and marked elevations in serum aminotransferase concentrations were rare. Weekly blood counts were required in the patients receiving continuation therapy, and those with lymphomas originating in the head and neck region received four doses of intrathecal chemotherapy, in addition to the daily oral mercaptopurine and weekly methotrexate. The patients who received nine weeks of chemotherapy alone were spared these side effects and the additional diagnostic and therapeutic interventions associated with continuation chemotherapy.
Discussion
The successful treatment of non-Hodgkin's lymphoma in children and young adults has evolved empirically since the early 1970s, when most patients with the disorder died. Although the use of intensive multimodal regimens proved to be successful in improving the prognosis for such patients,1,2,4,5,13-17 it became evident that patients with an early stage of disease had a more favorable prognosis than those with more advanced disease and might be curable with a reduction in treatment.3,6,7 We performed studies to identify the components of therapy that are necessary for a cure in patients with early-stage non-Hodgkin's lymphoma, allowing us to eliminate the components that provide no benefit and only contribute to toxic effects. We have been cautious in choosing the modifications to be tested and conservative in designing our studies in an effort not to compromise the efficacy of therapy.
The results of our latest study extend the observation made by us and other investigators3,6,7,18 that patients with early-stage non-Hodgkin's lymphoma can be treated successfully with a short course of chemotherapy of lessened intensity without irradiation of the primary sites of involvement and without continuation therapy. This treatment strategy is likely to reduce the acute side effects and financial and psychological costs of therapy, as well as the risk of late side effects, although further follow-up is necessary to confirm that the excellent outcome will be sustained and that the incidence of late side effects will be reduced. It might be argued that the elimination of 24 weeks of therapy with mercaptopurine and methotrexate, as well as four doses of intrathecal chemotherapy, represents a very small gain, because these drugs are associated with few late effects. However, the continued use of therapy that cannot be demonstrated to confer a benefit is not justifiable.
Not all patients benefited equally from our approach. The event-free survival of the patients with early-stage lymphoblastic lymphoma — a histologic subtype that accounts for approximately 15 percent of early-stage non-Hodgkin's lymphomas in children and young adults — was inferior to that of the patients with other subtypes of lymphoma. Moreover, the patients with early-stage lymphoblastic lymphoma — unlike those with other subtypes — appeared to benefit from continuation therapy. Although salvage therapy for the patients with early-stage lymphoblastic lymphoma who have relapses appears to be excellent (at least in the short term), further follow-up is necessary to determine whether they are cured. Other investigators have also recognized that patients with early-stage lymphoblastic lymphoma have a less favorable prognosis than those with other histologic subtypes and have treated such patients with more intensive therapies designed for advanced-stage disease.7,17,19,20 However, the overall outcome does not appear to be much improved with this approach.
Supported in part by grants (CA-33603, CA-29139, CA-31566, and CA-30969) from the National Cancer Institute.
We are indebted to the physicians and nurses at the participating institutions who cared for the patients and to the clinical research associates who assisted with the submission and analysis of the data.
Source Information
From the Departments of Pediatrics and Radiation Oncology, Stanford University School of Medicine and the Lucile Salter Packard Children's Hospital, Stanford, Calif. (M.P.L., S.S.D.); the Department of Statistics, University of Florida, and the Pediatric Oncology Group Statistical Office, Gainesville, Fla. (J.J.S.); the Department of Pathology, Saint Jude Children's Research Hospital and the University of Tennessee, Memphis (C.W.B.); and the Department of Pediatrics, Northwestern University School of Medicine and Children's Memorial Hospital, Chicago (S.B.M.).
Address reprint requests to Dr. Link at the Department of Pediatrics, Stanford University School of Medicine, 300 Pasteur Dr., Stanford, CA 94305-5208.
Appendix
The following members of the Pediatric Oncology Group participated in the study: Alberta Children's Hospital, Calgary, Alta., Canada; All Children's Hospital, St. Petersburg, Fla.; Baylor College of Medicine, Houston; Boston Floating Hospital, Boston; Bowman Gray School of Medicine, Winston-Salem, N.C.; Carolinas Medical Center, Charlotte, N.C.; Children's Hospital of San Diego, San Diego, Calif.; Children's Hospital of Michigan, Detroit; Children's Hospital of the Greenville Hospital System, Greenville, S.C.; Children's Memorial Hospital, Chicago; Children's Hospital of New Orleans, New Orleans; Cook–Fort Worth Children's Medical Center, Fort Worth, Tex.; Cross Cancer Institute, Edmonton, Alta., Canada; Dana–Farber Cancer Institute, Boston; Duke University Medical Center, Durham, N.C.; East Carolina University School of Medicine, Greenville, N.C.; Emory University School of Medicine, Atlanta; Fairfax Hospital, Fairfax, Va.; Hackensack Medical Center, Hackensack, N.J.; Johns Hopkins Hospital, Baltimore; Kaiser Permanente at San Diego, San Diego, Calif.; M.D. Anderson Cancer Center, Orlando, Fla.; Maine Children's Hospital, Portland; Massachusetts General Hospital, Boston; McGill University, Montreal; Medical College of Virginia, Richmond; Medical University of South Carolina, Charleston; Midwest Children's Cancer Center, Milwaukee; Mount Sinai Medical School, New York; Naval Medical Center, Portsmouth, Va.; Nemours Children's Clinic, Jacksonville, Fla.; Presbyterian Hospital, Charlotte, N.C.; Rhode Island Hospital, Providence; Roswell Park Memorial Institute, Buffalo, N.Y.; Sacred Heart Hospital, Pensacola, Fla.; Scott and White Memorial Hospital, Temple, Tex.; St. Christopher's Hospital for Children, Philadelphia; St. Francis Regional Medical Center, Wichita, Kans.; St. Jude Children's Research Hospital, Memphis, Tenn.; Stanford University School of Medicine, Stanford, Calif.; State University of New York at Syracuse, Syracuse; Swiss Pediatric Oncology Group, Bern, Geneva, and Lausanne, Switzerland; University of Alabama, Birmingham; University of Arkansas, Little Rock; University of California at Davis, Sacramento; University of California at San Diego, San Diego; University of Florida, Gainesville; University of Kansas Medical Center, Kansas City; University of Miami School of Medicine, Miami; University of Mississippi Medical Center, Jackson; University of Missouri Health Sciences Center, Columbia; University of New Mexico School of Medicine, Albuquerque; University of Oklahoma Health Sciences Center, Oklahoma City; University of Puerto Rico, San Juan; University of Rochester Medical Center, Rochester, N.Y.; University of South Alabama, Mobile; University of Texas Southwestern Medical School, Dallas; University of Texas at Galveston, Galveston; University of Vermont College of Medicine, Burlington; Walter Reed Army Medical Center, Washington, D.C.; Warren Clinics, Tulsa, Okla.; Washington University Medical Center, St. Louis; West Virginia University at Charleston, Charleston; West Virginia University at Morgantown, Morgantown; Wichita Community Clinical Oncology Program, Wichita, Kans.; and Yale University School of Medicine, New Haven, Conn.
- References
References
1
Murphy SB ,Fairclough DL ,Hutchison RE ,Berard CW . Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989;7:186-193
Web of Science | Medline2
Murphy SB ,Hustu HO . A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer 1980;45:630-637
CrossRef | Web of Science | Medline3
Murphy SB ,Hustu HO ,Rivera G ,Berard CW . End results of treating children with localized non-Hodgkin's lymphomas with a combined modality approach of lessened intensity. J Clin Oncol 1983;1:326-330
Web of Science | Medline4
Anderson JR ,Jenkin RDT ,Wilson JF , et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993;11:1024-1032
Web of Science | Medline5
Hvizdala EV ,Berard C ,Callihan T , et al. Nonlymphoblastic lymphoma in children -- histology and stage-related response to therapy: a Pediatric Oncology Group study. J Clin Oncol 1991;9:1189-1195
Web of Science | Medline6
Link MP ,Donaldson SS ,Berard CW ,Shuster JJ ,Murphy SB . Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990;322:1169-1174
Full Text | Web of Science | Medline7
Meadows AT ,Sposto R ,Jenkin RDT , et al. Similar efficacy of 6 and 18 months of therapy with four drugs (COMP) for localized non-Hodgkin's lymphoma of children: a report from the Childrens Cancer Study Group. J Clin Oncol 1989;7:92-99
Web of Science | Medline8
Murphy SB . Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-339
Web of Science | Medline9
The Non-Hodgkin's Lymphoma Pathologic Classification Project
CrossRef | Web of Science | Medline10
Peto R ,Peto J . Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-207
CrossRef | Web of Science11
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science12
Peto R ,Pike MC ,Armitage P , et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39
CrossRef | Web of Science | Medline13
Jenkin RDT ,Anderson JR ,Chilcote RR , et al. The treatment of localized non-Hodgkin's lymphoma in children: a report from the Children's Cancer Study Group. J Clin Oncol 1984;2:88-97
Web of Science | Medline14
Magrath IT ,Janus C ,Edwards BK , et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984;63:1102-1111
Web of Science | Medline15
Weinstein HJ ,Lack EE ,Cassady JR . APO therapy for malignant lymphoma of large cell “histiocytic“ type of childhood: analysis of treatment results for 29 patients. Blood 1984;64:422-426
Web of Science | Medline16
Sullivan MP ,Boyett J ,Pullen J , et al. Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer 1985;55:323-336
CrossRef | Web of Science | Medline17
Hvizdala EV ,Berard C ,Callihan T , et al. Lymphoblastic lymphoma in children -- a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group study. J Clin Oncol 1988;6:26-33
Web of Science | Medline18
Patte C ,Michon J ,Leverger G , et al. High survival rate of childhood B-cell lymphoma and leukemia (ALL) as result of the LMB 89 protocol of the SFOP (French Pediatric Oncology Society). Med Pediatr Oncol 1993;21:531-531 abstract.
Medline19
Patte C ,Kalifa C ,Flamant F , et al. Results of the LMT81 protocol,a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol 1992;20:105-113
CrossRef | Medline20
Tubergen DG ,Krailo MD ,Meadows AT , et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol 1995;13:1368-1376
Web of Science | Medline
- Citing Articles (50)
Citing Articles
1
Stéphane Ducassou, Céline Ferlay, Christophe Bergeron, Sandrine Girard, Geneviève Laureys, Hélène Pacquement, Dominique Plantaz, Patrick Lutz, Jean-Pierre Vannier, Anna Uyttebroeck, Yves Bertrand. (2011) Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. British Journal of Haematology 152:4, 441-451
CrossRef2
Philip Lanzkowsky. 2011. Non-Hodgkin Lymphoma. , 624-646.
CrossRef3
Angelo Rosolen, Lara Mussolin. 2010. Non-Hodgkin's Lymphoma. , 109-129.
CrossRef4
Lia Gore, Tanya M. Trippett. (2010) Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma. Current Hematologic Malignancy Reports 5:4, 177-184
CrossRef5
Thomas G. Gross, Gregory A. Hale, Wensheng He, Bruce M. Camitta, Jean E. Sanders, Mitchell S. Cairo, Robert J. Hayashi, Amanda M. Termuhlen, Mei-Jie Zhang, Stella M. Davies, Mary Eapen. (2010) Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents. Biology of Blood and Marrow Transplantation 16:2, 223-230
CrossRef6
Marilu Nelson, Sherrie L. Perkins, Bhavana J. Dave, Peter F. Coccia, Julia A. Bridge, Elizabeth R. Lyden, Nyla A. Heerema, Mark A. Lones, Lauren Harrison, Mitchell S. Cairo, Warren G. Sanger. (2010) An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG-5961. British Journal of Haematology 148:4, 600-610
CrossRef7
Marta Pillon, Matilde Piglione, Alberto Garaventa, Valentino Conter, Maria Giuliano, Giampaolo Arcamone, Rossella Mura, Monica Cellini, Emanuele S.G. D'Amore, Stefania Varotto, Lara Mussolin, Angelo Rosolen, . (2009) Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: A report of the Italian Association of pediatric hematology and oncology. Pediatric Blood & Cancer 53:6, 953-959
CrossRef8
Jessica Hochberg, Mitchell S. Cairo. (2009) Childhood and adolescent lymphoblastic lymphoma: End of the beginning and future directions. Pediatric Blood & Cancer 53:6, 917-919
CrossRef9
Thomas G. Gross. (2008) Where There are no Randomized, Phase 3 Trials—What is a Doctor to do?. Journal of Pediatric Hematology/Oncology 30:10, 719-720
CrossRef10
Alfred Reiter, Wolfram Klapper. (2008) Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. British Journal of Haematology 142:3, 329-347
CrossRef11
Robert E. Hutchison, Joseph H. Laver, Myron Chang, Tariq Muzzafar, Sunil Desai, Sharon Murphy, Molly Schwenn, Jonathan Shuster, Michael P. Link, . (2008) Non-anaplastic peripheral t-cell lymphoma in childhood and adolescence: A Children's Oncology Group study. Pediatric Blood & Cancer 51:1, 29-33
CrossRef12
Thomas G. Gross, Amanda M. Termuhlen. (2008) Pediatric non-Hodgkin lymphoma. Current Hematologic Malignancy Reports 3:3, 167-173
CrossRef13
Mary Gerrard, Mitchell S. Cairo, Claire Weston, Anne Auperin, Ross Pinkerton, Anne Lambilliote, Richard Sposto, Keith McCarthy, Marie-José T. Lacombe, Sherrie L. Perkins, Catherine Patte, . (2008) Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. British Journal of Haematology 141:6, 840-847
CrossRef14
Sameer Bakhshi, Talvir Sidhu. (2008) Pediatric orbital and ocular lymphomas. Pediatric Blood & Cancer 50:4, 940-941
CrossRef15
Howland E. Crosswell, Daniel J. Bergsagel, Robert Yost, Glen Lew. (2008) Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. Pediatric Blood & Cancer 50:4, 883-885
CrossRef16
Thomas G. Gross, Amanda M. Termuhlen. (2007) Pediatric non-Hodgkin’s lymphoma. Current Oncology Reports 9:6, 459-465
CrossRef17
Rodney R. Miles, Mitchell S. Cairo, Prakash Satwani, David L. Zwick, Mark A. Lones, Richard Sposto, Minnie Abromovitch, Sheryl Tripp, Anne L. Angiolillo, Elizabeth Roman, Virginia Davenport, Sherrie L. Perkins. (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. British Journal of Haematology 138:4, 506-512
CrossRef18
Himesh Gupta, Andrew M. Davidoff, Ching-Hon Pui, Stephen J. Shochat, John T. Sandlund. (2007) Clinical implications and surgical management of intussusception in pediatric patients with Burkitt lymphoma. Journal of Pediatric Surgery 42:6, 998-1001
CrossRef19
Marga Forns, Germán Javier, Jesús Estella, Rafael Fernández-Delgado, Soledad Gallego, Purificación García-Miguel, José M. Indiano, Aurora Navajas, Nuria Pardo. (2007) Resultados del protocolo SHOP LNHB98 (LMB89) en pacientes de edad pediátrica afectados de linfoma no hodgkiniano de células B. Medicina Clínica 128:17, 641-646
CrossRef20
Barton A. Kamen, Roger Strair. (2007) What is Learned From an Acronym? Convergence of Treatments and/or Diseases?. Journal of Pediatric Hematology/Oncology 29:5, 277-278
CrossRef21
J. T. Sandlund. (2007) Should Adolescents with NHL Be Treated as Old Children or Young Adults?. Hematology 2007:1, 297-303
CrossRef22
Mark A. Lones, Nyla A. Heerema, Michelle M. Le Beau, Richard Sposto, Sherrie L. Perkins, Marshall E. Kadin, Carl R. Kjeldsberg, Anna Meadows, Stuart Siegel, Jonathan Buckley, Minnie Abromowitch, John Kersey, Sharon Bergeron, Mitchell S. Cairo, Warren G. Sanger. (2007) Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genetics and Cytogenetics 172:1, 1-11
CrossRef23
A. Reiter. (2007) Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. Hematology 2007:1, 285-296
CrossRef24
Neerav N. Shukla, Tanya M. Trippett. (2006) Non-Hodgkin’s lymphoma in children and adolescents. Current Oncology Reports 8:5, 387-394
CrossRef25
Mitchell S. Cairo, Elizabeth Raetz, Megan S. Lim, Virginia Davenport, Sherrie L. Perkins. (2005) Childhood and adolescent non-Hodgkin lymphoma: New insights in biology and critical challenges for the future. Pediatric Blood & Cancer 45:6, 753-769
CrossRef26
Birgit Burkhardt, Martin Zimmermann, Ilske Oschlies, Felix Niggli, Georg Mann, Reza Parwaresch, Hansjoerg Riehm, Martin Schrappe, Alfred Reiter, . (2005) The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. British Journal of Haematology 131:1, 39-49
CrossRef27
Kadria Sayed, H. Savell, Robert E. Hutchison, James Kepner, Michael P. Link, Molly Schwenn, Hazem Mahmoud, David M. Parham. (2005) Review of Tonsillar Lymphoma in Pediatric Patients from the Pediatric Oncology Group: What Can Be Learned about Some Indications for Microscopic Examination?. Pediatric and Developmental Pathology 8:5, 533-540
CrossRef28
Ross Pinkerton. (2005) Continuing challenges in childhood non-Hodgkin's lymphoma. British Journal of Haematology 130:4, 480-488
CrossRef29
Jens Gille, Konstanze Spieth, Roland Kaufmann. (2005) Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. Metronomische niedrig-dosierte Chemotherapie als antiangiogene Therapiestrategie fur Tumorerkrankungen. Journal der Deutschen Dermatologischen Gesellschaft 3:1, 26-32
CrossRef30
Samar A. Muwakkit, Bassem I. Razzouk, Nina S. Shabb, Michael L. Hancock, Ibrahim Dabbous, Salim Firzli, Miguel R. Abboud. (2004) Clinical Presentation and Treatment Outcome of Children With Burkitt Lymphoma in Lebanon. Journal of Pediatric Hematology/Oncology 26:11, 749-753
CrossRef31
Robert S. Kerbel, Barton A. Kamen. (2004) The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer 4:6, 423-436
CrossRef32
Mark A. Lones, Warren G. Sanger, Michelle M. Le Beau, Nyla A. Heerema, Richard Sposto, Sherrie L. Perkins, Jonathan Buckley, Marshall E. Kadin, Carl R. Kjeldsberg, Anna Meadows, Stuart Siegel, Jonathan Finlay, Sharon Bergeron, Mitchell S. Cairo. (2004) Chromosome Abnormalities May Correlate With Prognosis in Burkitt/Burkitt-Like Lymphomas of Children and Adolescents. Journal of Pediatric Hematology/Oncology 26:3, 169-178
CrossRef33
Meghen B. Browning, Bruce M. Camitta. (2003) The Surgeonʼs Role in Pediatric Orbital Malignancies: An Oncologistʼs Perspective. Ophthalmic Plastic & Reconstructive Surgery 19:5, 340-344
CrossRef34
Sharon B. Murphy, Elaine R. Morgan, Howard M. Katzenstein, Morris Kletzel. (2003) Results of Little or No Treatment for Lymphocyte-Predominant Hodgkin Disease in Children and Adolescents. Journal of Pediatric Hematology/Oncology 25:9, 684-687
CrossRef35
Alan B. Astrow, Grace Tarabay, Vincent E. Salerno, William A. Cook, Robert Lin, Steven Lascher, Zujun Li, Amitabha Mazumder, Ira Halperin, John Cho, Zulfaqquar Jaffar, Marilyn McLaughlin, Ronald H. Blum, Sanford J. Kempin. (2003) Long-term survival in patients with human immunodeficiency virus-associated small non-cleaved cell lymphoma: the role for short course intensive chemotherapy. Hematological Oncology 21:3, 131-140
CrossRef36
Claudete Esteves Klumb, Daniel Rodrigues Furtado, Lidia Maria Magalhaes de Resende, Maria Kadma Carrico, Arthur Moellman Coelho, Ernesto Meis, Raquel Ciuvalschi Maia, Franklin David Rumjanek. (2003) DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. European Journal of Haematology 71:2, 81-90
CrossRef37
Sharon B Murphy. (2003) Research involving long-term survivors of childhood and adolescent cancer: issues impacting design and conduct of clinical trials. Current Problems in Cancer 27:4, 225-235
CrossRef38
G. A. Amos Burke, John Imeson, Rachel Hobson, Mary Gerrard. (2003) Localized non-Hodgkin's lymphoma with B-cell histology: cure without cyclophosphamide? A report of the United Kingdom Children's Cancer Study Group on studies NHL 8501 and NHL 9001 (1985-1996). British Journal of Haematology 121:4, 586-591
CrossRef39
Mitchell S. Cairo, Richard Sposto, Margo Hoover-Regan, Anna T. Meadows, James R. Anderson, Stuart E. Siegel, Marshall E. Kadin, Carl R. Kjeldsberg, John F. Wilson, Sherrie L. Perkins, Mark A. Lones, Erin Morris, Jonathan L. Finlay. (2003) Childhood and adolescent large-cell lymphoma (LCL): A review of the children's cancer group experience. American Journal of Hematology 72:1, 53-63
CrossRef40
Andrew M. Evens, Leo I. Gordon. (2002) Burkitt’s and Burkitt-like Lymphoma. Current Treatment Options in Oncology 3:4, 291-305
CrossRef41
Sheila Weitzman, Kaveri Suryanarayan, Howard J. Weinstein. (2002) Pediatric non-hodgkin’s lymphoma: Clinical and biologic prognostic factors and risk allocation. Current Oncology Reports 4:2, 107-113
CrossRef42
Olavo Pires de Camargo, Telma Murias dos Santos Machado, Alberto Tesconi Croci, Cl??udia Regina G. C. M. de Oliveira, Marcelo Abrantes Giannotti, Andr?? Mathias Baptista, Marcelo Tadeu Caiero, Ven??ncio Avancini F. Alves, Lucy Akemi Matsumoto. (2002) Primary Bone Lymphoma in 24 Patients Treated Between 1955 and 1999. Clinical Orthopaedics and Related Research 397, 271-280
CrossRef43
Rong-Long Chen, Pen-Jung Wang, Yung-Hsiung Hsu, Pau-Yuan Chang, Jye-Siung Fang. (2002) Severe Lung Fibrosis After Chemotherapy in a Child With Ataxia–Telangiectasia. Journal of Pediatric Hematology/Oncology 24:1, 77-79
CrossRef44
Wing Leung, John T. Sandlund, Melissa M. Hudson, Yinmei Zhou, Michael L. Hancock, Yunping Zhu, Raul C. Ribeiro, Jeffrey E. Rubnitz, Larry E. Kun, Bassem Razzouk, William E. Evans, Ching-Hon Pui. (2001) Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 92:7, 1959-1966
CrossRef45
Peter D. Inskip. (2001) Thyroid cancer after radiotherapy for childhood cancer. Medical and Pediatric Oncology 36:5, 568-573
CrossRef46
Olaf Neth, Kathrin Seidemann, Petra Jansen, Georg Mann, Markus Tiemann, Wolf-Dieter Ludwig, Hansj
rg Riehm, Alfred Reiter. (2000) Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90. Medical and Pediatric Oncology 35:1, 20-27
CrossRef47
Alan C. Aisenberg. (2000) Historical review of lymphomas. British Journal of Haematology 109:3, 466-476
CrossRef48
C. R. Pinkerton. (1999) The continuing challenge of treatment for non-Hodgkin's lymphoma in children. British Journal of Haematology 107:2, 220-234
CrossRef49
Claudio Sandoval, Michael Swift. (1998) Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Medical and Pediatric Oncology 31:6, 491-497
CrossRef50
Magrath, Ian, . (1997) Limiting Therapy for Limited Childhood Non-Hodgkin's Lymphoma. New England Journal of Medicine 337:18, 1304-1306
Full Text
